EAM Investors’s Aclaris Therapeutics ACRS Stock Holding History

EAM Investors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$906K	Sell	171,327 -7,051	-4%	-$31.4K	0.08%	233
2026 Q1	$669K	Buy	+178,378	New	+$602K	0.08%	242
2021 Q2	–	Sell	-205,295	Closed	-$5.17M	–	304
2021 Q1	$5.17M	Buy	+205,295	New	+$4.01M	0.78%	8
2017 Q2	–	Sell	-129,066	Closed	-$3.85M	–	292
2017 Q1	$3.85M	Sell	129,066 -9,550	-7%	-$275K	0.61%	29
2016 Q4	$3.76M	Buy	138,616 +106,649	+334%	+$2.72M	0.5%	38
2016 Q3	$819K	Sell	31,967 -4,175	-12%	-$88.6K	0.11%	273
2016 Q2	$668K	Buy	+36,142	New	+$716K	0.1%	289

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

EAM Investors's ACRS Position: Q2 2026 in Review

EAM Investors reduced its Aclaris Therapeutics (ACRS) stake by 4% in Q2 2026, selling an estimated $31.4K and leaving 171,327 shares worth $906K. The position accounts for 0.08% of the portfolio, ranked #233.

EAM Investors first reported a position in ACRS in Q2 2016 and has held it in 7 quarters since. The position peaked at $5.17M in Q1 2021. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

EAM Investors held 171,327 shares of Aclaris Therapeutics worth $906K as of Q2 2026.
EAM Investors sold 7,051 Aclaris Therapeutics shares in Q2 2026, an estimated $31.4K.
Aclaris Therapeutics made up 0.08% of EAM Investors's portfolio in Q2 2026, its #233 holding.
EAM Investors first reported a position in Aclaris Therapeutics in Q2 2016 and has held it in 7 quarters since.
EAM Investors's Aclaris Therapeutics position peaked at $5.17M in Q1 2021.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.